The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -3,623,353 |
| Depreciation expense | 25,113 |
| Net change in unrealized appreciation and depreciation in gold bullions | -110,198 |
| Gain on sale of gold bullions | 200,433 |
| Stock issued for services | 834,600 |
| Imputed interest - related party | 79,275 |
| Fair value of options issued for services | 22,748 |
| Warrants issued/(cancelled) to consultants | -259,493 |
| Decrease prepaid expenses | -10,799 |
| (increase) in inventory | 22,183 |
| Decrease in operating lease right-of-use, net | -55,663 |
| Increase in accrued expenses and other payables - related party | 947,747 |
| Decrease in accounts payable | -11,891 |
| Decrease in operating lease liabilities, current | -56,350 |
| Net cash used in operating activities | -1,788,970 |
| Proceeds from sale of investment in gold | 443,437 |
| Purchase of fixed assets | 5,395 |
| Net cash provided by investing activities | 438,042 |
| Proceeds from standby equity purchase agreement | 2,602,900 |
| Payment of debt offering costs | 10,000 |
| Principal payments on debt - related party | 125,000 |
| Net cash provided by financing activities | 2,467,900 |
| Net change in cash and cash equivalents | 1,116,972 |
| Cash and cash equivalents at beginning of year | 673,264 |
| Cash and cash equivalents at end of year | 1,790,236 |
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)